NCT06876701View on ClinicalTrials.gov

The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Acute Leukemia
Interventions
DRUG

Bevacizumab

Evaluation of the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults

Trial Locations (1)

Unknown

Shanghai Zhaxin integrated hospital of traditional Chinese and Western Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER